Published in J Am Coll Cardiol on December 29, 2009
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J (2014) 2.31
Natriuretic peptides: Diagnostic and therapeutic use. Indian J Endocrinol Metab (2011) 1.57
Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One (2013) 1.15
Novel biomarkers in chronic heart failure. Nat Rev Cardiol (2012) 1.06
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail (2014) 1.06
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study. BMJ (2013) 1.03
Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit Care (2011) 1.02
The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc (2011) 0.99
Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev (2014) 0.87
BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem (2013) 0.84
The potential value of integrated natriuretic peptide and echo-guided heart failure management. Cardiovasc Ultrasound (2014) 0.82
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol (2016) 0.79
Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients. Cardiovasc Diabetol (2013) 0.79
Incorporating common biomarkers into the clinical management of heart failure. Curr Heart Fail Rep (2013) 0.78
Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study. Heart (2015) 0.78
Correlation between B-Type Natriuretic Peptide and Functional/Cognitive Parameters in Discharged Congestive Heart Failure Patients. Int J Endocrinol (2015) 0.78
Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev (2015) 0.78
Natriuretic peptides as biomarkers in heart failure. J Investig Med (2013) 0.77
Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy? Clin Res Cardiol (2011) 0.77
Major themes for 2010 in cardiothoracic and vascular anesthesia. HSR Proc Intensive Care Cardiovasc Anesth (2011) 0.77
Natriuretic peptide-guided therapy for heart failure: ready for "battle" or too "scarred" by the challenges of trial design? J Am Coll Cardiol (2009) 0.76
Warning on diuretic use. J Am Coll Cardiol (2010) 0.75
Diagnostic values of NT-proBNP in acute dyspnea among elderly patients. Int J Clin Exp Pathol (2015) 0.75
Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. Am Heart J (2016) 0.75
A review on B-type natriuretic peptide monitoring: assays and biosensors. Heart Fail Rev (2016) 0.75
Battlescarred: subgroup or selection bias? J Am Coll Cardiol (2010) 0.75
Almanac 2011: Heart Failure. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology. Mater Sociomed (2011) 0.75
Evolution of biomarker guided therapy for heart failure: current concepts and trial evidence. Curr Cardiol Rev (2015) 0.75
Biomarker-guided therapy for heart failure. Indian Heart J (2012) 0.75
Associates of an elevated natriuretic peptide level in stable heart failure patients: implications for targeted management. ScientificWorldJournal (2013) 0.75
Can Natriuretic Peptides be Used to Guide Therapy? EJIFCC (2016) 0.75
NT-proBNP-guided and clinically guided treatment reduced short-term but not long-term mortality in chronic HF. Ann Intern Med (2010) 0.75
B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev (2014) 0.75
Ambulatory pulmonary artery pressure monitoring in advanced heart failure patients. World J Cardiol (2017) 0.75
A new signal from B-type natriuretic peptide in ST-elevation myocardial infarction: what does it mean for B-type natriuretic peptide and innovative diagnostics? Circulation (2010) 0.75
Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. BMC Cardiovasc Disord (2016) 0.75
Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open (2016) 0.75
Ambulatory Heart Failure Monitoring: A Systemic Review. Cureus (2017) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
The impact of cardiac resynchronization therapy on routine laboratory parameters. Interv Med Appl Sci (2017) 0.75
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet (2011) 5.61
Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int (2010) 3.37
2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol (2012) 3.15
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int (2011) 3.05
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol (2007) 2.60
Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. Ann Surg (2008) 2.50
Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation (2005) 2.34
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol (2013) 2.28
B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation (2010) 2.26
B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation (2003) 2.22
Holmium laser enucleation of the prostate: results at 6 years. Eur Urol (2007) 2.07
Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol (2005) 2.05
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J (2008) 2.04
Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. J Am Coll Cardiol (2005) 1.99
Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J (2008) 1.85
Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract (2007) 1.85
Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res (2009) 1.83
Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol (2003) 1.80
Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol (2010) 1.77
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord (2010) 1.72
Urocortin 2 infusion in human heart failure. Eur Heart J (2007) 1.67
Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol (2007) 1.66
The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev (2007) 1.62
Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J (2008) 1.58
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol (2003) 1.55
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int (2010) 1.54
Serial Doppler echocardiography and tissue Doppler imaging in the detection of elevated directly measured left atrial pressure in ambulant subjects with chronic heart failure. JACC Cardiovasc Imaging (2011) 1.54
Early dynamic change in high-sensitivity cardiac troponin T in the investigation of acute myocardial infarction. Clin Chem (2011) 1.54
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J (2006) 1.52
Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care (2010) 1.50
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther (2009) 1.49
Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens (2002) 1.49
PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision. N Z Med J (2007) 1.48
ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail (2012) 1.47
Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol (2011) 1.44
High-sensitivity troponin T for early rule-out of myocardial infarction in recent onset chest pain. Emerg Med J (2011) 1.44
Effectiveness of computerised cognitive behaviour therapy for anxiety disorders in secondary care. Aust N Z J Psychiatry (2012) 1.44
Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int (2011) 1.44
Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation (2007) 1.43
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
N-terminal pro-C-type natriuretic peptide, but not C-type natriuretic peptide, is greatly elevated in the fetal circulation. Clin Sci (Lond) (2004) 1.41
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol (2004) 1.41
A call for screening for benign neutropenia in Arab populations. Saudi Med J (2011) 1.40
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation (2003) 1.38
New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol (2010) 1.38
Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. J Am Coll Cardiol (2012) 1.37
Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation (2010) 1.36
Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol (2008) 1.35
Comprehensive undergraduate medical assessments improve prediction of clinical performance. Med Educ (2004) 1.35
Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol (2007) 1.31
Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). Am J Cardiol (2005) 1.31
Evaluation of trial outcomes in acute kidney injury by creatinine modeling. Clin J Am Soc Nephrol (2009) 1.29
Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol (2006) 1.25
A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortality. Circ Cardiovasc Genet (2010) 1.21
Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail (2012) 1.21
Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol (2003) 1.20
Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail (2013) 1.20
Genomic selection of reference genes for real-time PCR in human myocardium. BMC Med Genomics (2008) 1.19
The effect of ambient air pollution on respiratory health of school children: a panel study. Environ Health (2008) 1.18
Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail (2008) 1.18
Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol (2011) 1.17
Demographics and microbiological profile of pneumonia in United Arab Emirates. Monaldi Arch Chest Dis (2006) 1.14
Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care (2012) 1.13
Right atrial volume index in chronic systolic heart failure and prognosis. JACC Cardiovasc Imaging (2009) 1.12
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J (2006) 1.11
Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol (2008) 1.09
Association of TCF7L2 polymorphism with diabetes mellitus, metabolic syndrome, and markers of beta cell function and insulin resistance in a population-based sample of Emirati subjects. Diabetes Res Clin Pract (2008) 1.08
Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) (2005) 1.06
Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol (2007) 1.06
Severe obstructive sleep apnea and outcomes following myocardial infarction. J Clin Sleep Med (2011) 1.06
Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol (2002) 1.05